1. Home
  2. IIF vs TNXP Comparison

IIF vs TNXP Comparison

Compare IIF & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Morgan Stanley India Investment Fund Inc.

IIF

Morgan Stanley India Investment Fund Inc.

HOLD

Current Price

$22.66

Market Cap

203.7M

Sector

Finance

ML Signal

HOLD

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$13.35

Market Cap

172.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IIF
TNXP
Founded
1993
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
203.7M
172.7M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
IIF
TNXP
Price
$22.66
$13.35
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
46.4K
452.3K
Earning Date
01-01-0001
05-11-2026
Dividend Yield
13.94%
N/A
EPS Growth
N/A
91.75
EPS
N/A
N/A
Revenue
N/A
$13,107,000.00
Revenue This Year
N/A
$558.11
Revenue Next Year
N/A
$38.29
P/E Ratio
N/A
N/A
Revenue Growth
N/A
29.85
52 Week Low
$19.83
$11.60
52 Week High
$28.37
$69.65

Technical Indicators

Market Signals
Indicator
IIF
TNXP
Relative Strength Index (RSI) 61.92 46.56
Support Level $19.83 $13.32
Resistance Level $27.38 $20.36
Average True Range (ATR) 0.44 1.02
MACD 0.34 -0.03
Stochastic Oscillator 95.48 40.17

Price Performance

Historical Comparison
IIF
TNXP

About IIF Morgan Stanley India Investment Fund Inc.

Morgan Stanley India Investment Fund, Inc. is the United States based non-diversified, closed-end management investment company. Its investment objective is to achieve long-term capital appreciation through investment in equity securities of Indian Issuers. The company's portfolio of investments consists of the investment in different sectors such as auto components, banks, capital markets, construction and engineering, pharmaceuticals and others.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

Share on Social Networks: